Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
Cancer. 1993 Feb 15;71(4):1266-72. doi: 10.1002/1097-0142(19930215)71:4<1266::aid-cncr2820710416>3.0.co;2-k.
Influence of tamoxifen treatment on estrogen receptor (ER) and progesterone receptor (PR) levels in human breast cancer has not been fully elucidated in vivo. This problem was studied in 20 postmenopausal patients with ER-positive and PR-positive primary breast cancer.
Each patient underwent two fine-needle aspiration (FNA) biopsies. Between two FNA, 10 patients received no treatment (control group) and the other 10 patients were given tamoxifen (20 mg/day) for an average of 8 days (range, 6-10 days) (TAM group). Total ER and PR values (cytosolic plus nuclear fraction) in FNA samples were determined by enzyme immunoassay (EIA) for detecting ER and PR regardless of their occupancy with corresponding ligands.
In the control group, no significant difference was found in ER and PR values between the first and second FNA samples. In the TAM group, ER and PR values (mean +/- standard error of the mean [SEM] fmol/mg DNA) in the second FNA samples were 605 +/- 186 and 1130 +/- 344, respectively, and were significantly higher (P < 0.05) than ER and PR values in the first FNA samples, which were 312 +/- 74 and 639 +/- 159, respectively. ER and PR values increased by 201 +/- 27% and 163 +/- 23%, respectively, on an individual basis after tamoxifen treatment.
These results demonstrated that tamoxifen up-regulates ER and PR in human breast cancer.
他莫昔芬治疗对人乳腺癌中雌激素受体（ER）和孕激素受体（PR）水平的影响在体内尚未完全阐明。本研究在20例绝经后ER阳性和PR阳性原发性乳腺癌患者中探讨了这一问题。
每位患者均接受两次细针穿刺（FNA）活检。在两次FNA之间，10例患者未接受治疗（对照组），另外10例患者给予他莫昔芬（20mg/天），平均治疗8天（范围6 - 10天）（TAM组）。通过酶免疫测定（EIA）测定FNA样本中总的ER和PR值（胞质加核部分），以检测ER和PR，而不考虑其与相应配体的结合情况。
对照组中，第一次和第二次FNA样本的ER和PR值无显著差异。在TAM组中，第二次FNA样本的ER和PR值（平均±均值标准误[SEM]fmol/mg DNA）分别为605±186和1130±344，显著高于第一次FNA样本中的ER和PR值，第一次分别为312±74和639±159。他莫昔芬治疗后，个体的ER和PR值分别增加了201±27%和163±23%。
这些结果表明他莫昔芬可上调人乳腺癌中的ER和PR。
